Mayne Pharma's market capitalization fluctuates continuously in accordance with daily share price movements on the Australian Securities Exchange and prevailing foreign exchange rates between the Australian dollar and the U.S. dollar. Based on recent trading valuations reflecting its small-cap equity status, the company's total market capitalization translates roughly to approximately $160 million to $180 million USD. Because micro-cap and small-cap healthcare equities experience frequent valuation adjustments driven by quarterly earnings reports and investor sentiment, exact market cap figures require verification via real-time financial tracking terminals.